2023
Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial
Mc Causland F, Hsu J, Himmelfarb J, Ikizler T, Raj D, Mehrotra R, Waikar S, Kimmel P, Kliger A, Dember L, Charytan D, Kliger A, Charytan D, Mc Causland F, Robinson E, Waikar S, Williams M, Weiner D, Aurien-Blajeni E, Cinelli M, Nizam T, Rim S, Seok P, Smith C, Curtis J, Raj D, Regunathan-Shenk R, Sharma S, Ramezani A, Andrews S, Dumadag M, Franco C, Wing M, Himmelfarb J, Mehrotra R, Anderson L, Linke L, Manahan L, Ikizler T, Hung A, Cavanaugh K, Booker C, Brannon B, Clagett A, Ellis C, Dember L, Landis J, Anderson A, Hsu J, Cifelli D, Ballard S, Durborow M, Howard T, Kuzla N, Nessel L, Tierney A, Skali H, Solomon S, Rad A, Di Carli M, Gaber M, Foster C, Kimmel P, Kusek J. Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial. Kidney360 2023, 4: e486-e495. PMID: 36763641, PMCID: PMC10278797, DOI: 10.34067/kid.0000000000000067.Peer-Reviewed Original ResearchMeSH KeywordsArrhythmias, CardiacHumansMineralocorticoid Receptor AntagonistsRenal DialysisSpironolactoneConceptsEffect of spironolactoneFrequency of bradycardiaMaintenance hemodialysisFollow-upPost hoc analysisConduction blockArrhythmic eventsCardiovascular eventsMaintenance HDSudden deathHoc analysisIncidence of cardiovascular eventsAssociation of spironolactoneDose of spironolactoneRisk of cardiovascular eventsDouble-blind trialProportion of patientsPatients treated with maintenance HDRandomized controlled trialsGeneralized estimating equation modelsSpironolactone groupPlacebo-controlledSpironolactone treatmentBradycardic eventsAge of participants
2022
A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Dember L, Hung A, Mehrotra R, Hsu J, Raj D, Charytan D, Mc Causland F, Regunathan-Shenk R, Landis J, Kimmel P, Kliger A, Himmelfarb J, Ikizler T, Consortium H. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney International 2022, 102: 1178-1187. PMID: 35863559, PMCID: PMC9588554, DOI: 10.1016/j.kint.2022.06.022.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesPlacebo groupAdverse eventsMedian decreaseHemodialysis patientsIL-6IL-1 receptor antagonistRate of adverse eventsEffect of anakinraPlacebo-controlled trialBaseline to weekAnti-cytokine therapyIL-1 inhibitionAssociated with morbidityAnakinra groupReceptor antagonistBetween-group differencesEfficacy outcomesAnakinraMaintenance hemodialysisRandomized controlled pilot trialChronic inflammationEvaluate safetyPlaceboIL-1
2021
The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study.
Raj D, Sohn M, Charytan D, Himmelfarb J, Ikizler T, Mehrotra R, Ramezani A, Regunathan-Shenk R, Hsu J, Landis J, Li H, Kimmel P, Kliger A, Dember L. The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. Kidney360 2021, 2: 445-455. PMID: 35369018, PMCID: PMC8786005, DOI: 10.34067/kid.0006132020.Peer-Reviewed Original ResearchConceptsGut microbiomeStool samplesMicrobiome compositionMetabolomic profilesCLINICAL TRIAL REGISTRY NAMEWeighted UniFrac distancesStudy of patientsTRIAL REGISTRY NAMEUniFrac distancesMicrobiome diversityPretreatment to post-treatmentMaintenance hemodialysisUremic toxicityClinical trialsIntestinal microbiomeMicrobiomePost-treatmentREGISTRY NAMEGutPatientsHemodialysisMetabolome compositionFrequent sample collectionRegistration numberESKD
2020
Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.
Charytan D, Hsu J, Mc Causland F, Waikar S, Ikizler T, Raj D, Landis J, Mehrotra R, Williams M, DiCarli M, Skali H, Kimmel P, Kliger A, Dember L, Himmelfarb J, Anderson A, Hung A, Sharma S, Weiner D. Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360 2020, 1: 1380-1389. PMID: 35372900, PMCID: PMC8815530, DOI: 10.34067/kid.0004342020.Peer-Reviewed Original ResearchMeSH KeywordsHumansHydralazineIsosorbide DinitrateKidney Failure, ChronicPilot ProjectsRenal DialysisTomography, X-Ray ComputedConceptsIsosorbide dinitrateCoronary flow reserveAdverse eventsMaintenance HDMitral annular e' velocityDouble-blind pilot trialFlow reserveRecurrent intradialytic hypotensionRandomized to placeboMaximum tolerated doseTissue Doppler echocardiographyParticipants discontinued therapyGastrointestinal side effectsDetect between-group differencesPilot trialIntra-dialytic hypotensionPlacebo-ControlledPositron emission tomographyDose escalationHeart failure mortalityDose reductionStudy medicationTolerated dosePlacebo groupCombination therapy
2010
In-Center Hemodialysis Six Times per Week versus Three Times per Week
Chertow G, Levin N, Beck G, Depner T, Eggers P, Gassman J, Gorodetskaya I, Greene T, James S, Larive B, Lindsay R, Mehta R, Miller B, Ornt D, Rajagopalan S, Rastogi A, Rocco M, Schiller B, Sergeyeva O, Schulman G, Ting G, Unruh M, Star R, Kliger A. In-Center Hemodialysis Six Times per Week versus Three Times per Week. New England Journal Of Medicine 2010, 363: 2287-2300. PMID: 21091062, PMCID: PMC3042140, DOI: 10.1056/nejmoa1001593.Peer-Reviewed Original ResearchConceptsLeft ventricular massPhysical health composite scoresFrequent hemodialysisComposite outcomeVascular accessVentricular massSelf-reported depressionConventional hemodialysisCardiac magnetic resonance imagingConventional hemodialysis groupErythropoiesis-stimulating agentsRate of hospitalizationSerum albumin concentrationComposite scoreSelf-reported physical healthCognitive performanceMagnetic resonance imagingMaintenance hemodialysisSecondary outcomesBlood pressureLaboratory markersCenter hemodialysisClinical trialsMineral metabolismHealth Survey
2001
Patient Safety in End-Stage Renal Disease: How Do We Create a Safe Environment?
Kliger A, Diamond L. Patient Safety in End-Stage Renal Disease: How Do We Create a Safe Environment? Advances In Kidney Disease And Health 2001, 8: 131-137. PMID: 11349254, DOI: 10.1053/jarr.2001.23991.Commentaries, Editorials and Letters
1996
The Incident Patient Cohort Study Design With Uncontrolled Dose
GOTCH F, GENTILE D, KEEN M, AMERLING R, FOLKERT V, KLIGER A, SHAPIRO W. The Incident Patient Cohort Study Design With Uncontrolled Dose. ASAIO Journal 1996, 42: m514-517. PMID: 8944932, DOI: 10.1097/00002480-199609000-00039.Peer-Reviewed Original ResearchConceptsPeritoneal dialysisContinuous ambulatory peritoneal dialysisAmbulatory peritoneal dialysisCohort study designClinical outcome studiesRenal urea clearanceDialysis prescriptionSingle dosesDose equivalencyRelative riskDialysis doseMortality riskOutcome studiesDose levelsUrea clearanceStudy designMonth intervalsD responseHemodialysisDialysisDoseDosesRiskMortalityWide variance
1980
Medical Condition, Adherence to Treatment Regimens, and Family Functioning: Their Interactions in Patients Receiving Long-term Dialysis Treatment
Steidl J, Finkelstein F, Wexler J, Feigenbaum H, Kitsen J, Kliger A, Quinlan D. Medical Condition, Adherence to Treatment Regimens, and Family Functioning: Their Interactions in Patients Receiving Long-term Dialysis Treatment. JAMA Psychiatry 1980, 37: 1025-1027. PMID: 7416903, DOI: 10.1001/archpsyc.1980.01780220063006.Peer-Reviewed Original ResearchMeSH KeywordsAdultCommunicationFamilyHumansParent-Child RelationsPatient CompliancePeritoneal DialysisRenal DialysisConceptsLong-term dialysis treatmentMedical conditionsDialysis treatmentOverall family functioningOverall medical conditionFamily functioningRatings of adherenceStable patientsTreatment regimensPoor adherenceEarly identificationPatientsAdherenceTreatmentSignificant correlationFamily assessmentMedical progressSignificant relationshipRegimensFunctioningFamily variables